Cardiome Pharma Corporation (CRME)
(Real Time Quote from BATS)
$2.33 USD
-0.05 (-2.10%)
Updated May 16, 2018 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[CRME]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Cardiome Becomes Correvio; Trevyent Plans on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Cipher Agreement Could Jumpstart a Stage of Strong Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Cardiome announced that it has entered into an agreement with Cipher Pharmaceuticals
Provider: Bloom Burton & Company
Analyst: MARTIN D
Industry: Medical - Drugs
Cipher Agreement Brings Relief and Opportunities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
2018 Top Ideas; Healthcare Sector Review/Preview
Provider: Bloom Burton & Company
Industry: Medical - Drugs
Zevtera Is a Sound Addition to Product Portfolio; Trevyent Filings in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q-2017 Preview
Provider: Bloom Burton & Company
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Market Overreaction to FDA News Creates Good Entry Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Drugs
Industry: Medical - Drugs
Xydalba to Drive Growth in 2H17; Trevyent Filings by Year End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical - Drugs
2Q-2017 Preview
Provider: Bloom Burton & Company
Industry: Medical - Drugs
EU Formularies Favorable on Xydalba; Treyvent MAA in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S